Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg)

Angeles Perez-Aisa,Olga P. Nyssen, Alma Keco-Huerga,Luis Rodrigo,Alfredo J. Lucendo, Blas J. Gomez-Rodriguez, Juan Ortuno, Monica Perona,Jose Maria Huguet, Oscar Nunez, Luis Fernandez-Bermejo,Jesus Barrio,Angel Lanas, Eduardo Iyo, Pilar Mata Romero, Miguel Fernandez-Bermej, Barbara Gomez, Ana Garre, Judith Gomez-Camarero, Luis Javier Lamuela,Ana Campillo, Luisa de la Pena-Negro, Manuel Dominguez Cajal,Luis Bujanda,Diego Burgos-Santamaria,Fernando Bermejo, Victor Gonzalez-Carrera, Ramon Pajares, Pedro Almela Notari, Javier Tejedor-Tejada,Montserrat Planella, Itxaso Jimenez, Yolanda Arguedas Lazaro, Antonio Cuadrado-Lavin,Isabel Perez-Martinez, Edurne Amorena,Jesus M. Gonzalez-Santiago, Teresa Angueira, Virginia Flores,Samuel J. Martinez-Dominguez,Manuel Pabon-Carrasco, Benito Velayos,Alicia Algaba, Consuelo Ramirez, Enrique Alfaro Almajano,Manuel Castro-Fernandez, Noelia Alcaide,Patricia Sanz Segura, Anna Cano-Catala, Natalia Garcia-Morales,Leticia Moreira,Francis Megraud,Colm O'Morain,Xavier Calvet,Javier P. Gisbert

GUT(2023)

引用 0|浏览4
暂无评分
摘要
BackgroundThe recommended schedule for single capsule bismuth quadruple therapy (scBQT, Pylera) includes a proton pump inhibitor (PPI) two times a day and three scBQT capsules four times a day. Four times a day treatments are inconvenient and reduce adherence. In contrast, adherence improves with three times a day schedules. In clinical practice, many gastroenterologists use four capsule scBQT three times a day. However, the effectiveness and safety of this latter approach remain uncertain. AimTo assess the effectiveness and safety of scBQT administered three times a day in the patients included in the European Registry on Helicobacter pylori Management (Hp-EuReg). MethodsAll Spanish adult patients registered in the Asociacion Espanola de Gastroenterologia Research Electronic Data Capture (REDCap) database from June 2013 to March 2021 receiving 10-day scBQT were analysed. Modified intention-to-treat effectiveness, adherence and the safety of scBQT given three times a day were calculated and compared with the four times a day schedule. A multivariate analysis was performed to determine independent factors predicting cure of the infection. ResultsOf the 3712 cases, 2516 (68%) were four times a day and 1196 (32%) three times a day. Mean age was 51 years, 63% were women and 15% had a peptic ulcer. The three times a day schedule showed significantly better overall cure rates than four times a day (1047/1112, 94%; 95% CI 92.7 to 95.6 vs 2207/2423, 91%; 95% CI 89.9 to 92.2, respectively, p=0.002). Adherence and safety data were similar for both regimens. In the multivariate analysis, three times a day dosage, first-line therapy, use of standard or high-dose PPIs and adherence over 90% were significantly associated with cure of the infection. ConclusionsScBQT prescribed three times a day was more effective than the traditional four times a day schedule. No differences were observed in treatment adherence or safety.
更多
查看译文
关键词
helicobacter pylori
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要